Research programme: matrix metalloproteinase inhibitors - Pfizer
Alternative Names: UK-370,106Latest Information Update: 05 Sep 2006
At a glance
- Originator Pfizer
- Class
- Mechanism of Action Matrix metalloproteinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer; Skin ulcer; Wounds
Most Recent Events
- 05 Sep 2006 Discontinued - Preclinical for Cancer in USA (unspecified route)
- 05 Sep 2006 Discontinued - Preclinical for Skin ulcer in United Kingdom (Topical)
- 05 Sep 2006 Discontinued - Preclinical for Wounds in United Kingdom (Topical)